FindTrial
Sign In

Real world use of biomarker testing using blood-based liquid biopsy in Japan

Real world use of biomarker testing using blood-based liquid biopsy in Japan - Real world use of biomarker testing using blood-based liquid biopsy in Japan

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000058648
Enrollment
Unknown
Registered
2025-07-30
Start date
2023-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant tumor

Interventions

None listed

Sponsors

MSD K.K
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who have at least 1 record for a liquid biopsy test (FoundationOne Liquid or Guardant360).

Exclusion criteria

Exclusion criteria: There are no exclusion criteria for this study.

Design outcomes

Primary

MeasureTime frame
Treatment pattern before and after CGP (cancer genomic profiling), Biomarker testing pattern—

Secondary

MeasureTime frame
Specific genomic status (EGFR, KRAS, MSI, TMB or other actionable mutations)—

Countries

Japan

Contacts

Public ContactJumpei Tetsuka

MSD K.K Medical Affairs

jumpei.tetsuka@merck.com03-6272-1000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026